Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) have received a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $30.56.
EXEL has been the topic of several research analyst reports. TheStreet cut shares of Exelixis from a “b-” rating to a “c+” rating in a research report on Tuesday, September 13th. Piper Sandler upped their target price on Exelixis from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 26th. Morgan Stanley upped their target price on Exelixis from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Friday, July 15th. BMO Capital Markets assumed coverage on Exelixis in a research note on Thursday, June 23rd. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Cowen upped their target price on Exelixis to $26.00 in a research note on Monday, August 15th.
Exelixis Trading Up 0.1 %
EXEL stock opened at $17.15 on Monday. The company’s 50 day moving average is $19.65 and its 200 day moving average is $20.41. The stock has a market cap of $5.52 billion, a price-to-earnings ratio of 20.42, a price-to-earnings-growth ratio of 0.54 and a beta of 0.65. Exelixis has a 1-year low of $15.50 and a 1-year high of $23.40.
Institutional Trading of Exelixis
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC lifted its stake in Exelixis by 72.4% in the first quarter. Quadrant Capital Group LLC now owns 1,241 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 521 shares during the period. Covestor Ltd raised its holdings in Exelixis by 245.6% in the first quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,191 shares in the last quarter. Total Clarity Wealth Management Inc. bought a new position in Exelixis in the second quarter worth $36,000. First Horizon Advisors Inc. raised its holdings in Exelixis by 296.7% in the second quarter. First Horizon Advisors Inc. now owns 2,440 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 1,825 shares in the last quarter. Finally, IndexIQ Advisors LLC bought a new position in Exelixis in the first quarter worth $61,000. Hedge funds and other institutional investors own 85.25% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.